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Objective: The practice of using fenestrated endografts to treat juxtarenal and group IV thoracoabdominal aortic aneu-
rysms (TAAAs) has become more accepted, but long-term outcomes are still unknown. We report long-term survival,
complications, and branch-related outcomes from a single-center experience.
Methods: The study included consecutive patients enrolled prospectively into a physician-sponsored investigational device
exemption classiﬁed as undergoing group IV TAAA or juxtarenal aneurysm repair by the treating surgeon using fenes-
trated endografts. Device morphology was used to subclassify this group of patients. Long-term survival and a composite
outcome of secondary intervention, branch occlusion, stent migration, endoleak, aneurysm growth, or spinal cord injury
were calculated. Descriptive analysis of branch-related outcomes and need for any reintervention was performed. Uni-
variate and multivariate analysis of mortality and the composite outcome was performed to determine associative risks.
Results: Long-term survival for patients with juxtarenal and group IV TAAA aneurysms treated with fenestrated stent
grafts was 20% at 8 years. Multivariate analysis showed long-term survival for this patient population was negatively
associated with increasing age, congestive heart failure, cancer, and previous aneurysm repair. The risk of spinal cord
ischemia (SCI) in this group was 1.2% and of aortic-related mortality was 2%. The risk of a spinal event increased with
coverage above the celiac artery (52 mm of coverage above the celiac artery in patients with SCI vs 33 mm without SCI;
P [ .099). More complex device conﬁgurations were more likely to require an increased rate of reinterventions, and
patients with celiac fenestrations were more likely to experience celiac occlusion over time (3.5% vs 0.5%; P [ .019).
However, less complex designs were complicated by an increased risk of type I endoleak over time (10.4% for renal
fenestrations only vs 1.9% for others; P < .01). As experience evolved, there was a trend to increase the number of fen-
estrations in devices treating the same anatomy.
Conclusions: The use of fenestrated devices to treat juxtarenal and group IV TAAA is safe and effective in long-term
follow-up. Mortality in this patient population is largely not aortic-related. Devices designed for fenestrated repair of
juxtarenal and group IV thoracoabdominal aneurysms within a physician sponsored investigational device exemption have
changed over time. Further research is needed to determine the best conﬁguration to treat aneurysms requiring coverage
proximal to the celiac artery. (J Vasc Surg 2015;61:355-64.)
The use of fenestrated stent grafts to treat aneurysms
with short infrarenal necks began in 1999.1 After proof-of-
concept was established, the number of branches routinely
incorporated has increased with time, complexity of disease,
and surgeon conﬁdence.2 The use of fenestrated stent grafts
has grown, and the long-term durability of these devices has
recently been reported.3,4 Analysis of these long-term results
suggests that longer landing zones are favored by some
expert groups in patients with similar anatomy, compared
with previous practice, because of the risk of long-term pro-
gression of aortic disease and the threat of device failure.2,5
With the advent of off-the-shelf devices and the recent
interest in chimney and snorkel techniques, surgeons will
have more options for treating aneurysms with landing
zones in the visceral aorta.6 Although technical success is
important, the focus of clinical decision making should
be long-term durability as it relates to preoperative vari-
ables such as device design and aortic anatomy.3,5 The liter-
ature is difﬁcult to interpret because of overlapping
deﬁnitions of juxtarenal, suprarenal, and type IV thora-
coabdominal aortic aneurysm (TAAA).
This report describes our outcomes with devices seal-
ing in or near the visceral aorta, which have been classiﬁed
as juxtarenal and type IV thoracoabdominal aneurysms by
the treating surgeon. Short-term technical and periopera-
tive outcomes are described as well as long-term success
and durability. Our goal was to determine the long-term
durability and risk of failure of fenestrated devices for
type IV TAAA and juxtarenal aneurysms.
METHODS
The series included all patients who underwent place-
ment of a branched or fenestrated endograft for treatment
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of juxtarenal or type IV thoracoabdominal aneurysm, as
classiﬁed by the treating surgeon, under a physician-
sponsored investigational device exemption protocol
between 2001 and December 2013 (ClinicalTrials.gov
identiﬁer NCT00583050). Details of the patient popula-
tion, device design, and methods of implantation have
been previously described.3,7-10 Design of the devices was
determined by the treating surgeon and evolved over
time based on the experience accrued at our center. All pa-
tients signed an informed consent approved by the Investi-
gational Review Board before device implantation.
Study outcomes. Patient outcome data and informa-
tion about imaging end points were included in a pro-
spectively maintained database (Oracle Clinical; Oracle
Corporation, Redwood Shores, Calif). A standard procedure
was followed for assessing imaging outcome events
by the treating vascular surgeon and a trained vascular imag-
ing specialist using a high-resolution, contrast-enhanced
computed tomography scan. Additional information was
acquired from duplex ultrasound studies and abdominal
radiography, where appropriate. Criteria for duplex imaging
and methods for computed tomography scan interpretation
have been previously reported.9,10 Discrepancies were
adjudicated independently by a surgeon with expertise in the
ﬁeld. Reporting standards documented for thoracic aneu-
rysm repair were followed to report imaging outcomes.11
The graft plans of all patients noted to have juxtarenal
or type IV thoracoabdominal aneurysm were reanalyzed
and captured retrospectively by one author (T.M.M.)
because this was not captured in our prospective database.
In analyzing these data, it became clear that the deﬁnitions
of type IV TAAA and juxtarenal aneurysm evolved over
time and were not consistent between operators. To create
more objective groups, patients were recategorized
into one of four groups depending on the most proximal
fenestration or scallop, which we deﬁned as “device
morphology:” fenestrated devices involving only renals
(renal), devices with fenestrations or scallops for the supe-
rior mesenteric artery (SMA), devices with scallops for the
celiac artery (celiac scallop), and devices with fenestrations
to the celiac, or landing zones above the celiac, implying a
length of graft material above the celiac (supraceliac). The
type of fenestration or scallop was then documented for
each vessel in each graft. When necessary, original imaging
was reviewed to be sure that documentation was accurate.
The main outcome was long-term durability of juxtare-
nal and type IV thoracoabdominal aneurysm repair using
fenestrated devices, as characterized by a composite of
mortality, reintervention, and branch occlusion. In addi-
tion, we assessed perioperative factors such as technical suc-
cess rate, branch-related outcomes, spinal cord injury, renal
complications, secondary intervention, development of
type I endoleak, and rupture.
We further assessed the durability of different fenestra-
tion types and related mating stent conﬁgurations to deter-
mine if there was a more successful combination. Another
goal was to assess the learning curve associated with
different branch conﬁgurations based on perioperative
complications and determine whether this had any effect
on long-term durability of the device. The short-term
and long-term outcomes of patients with single-wide scal-
lops were analyzed. Using these data, we hoped to better
distinguish between anatomic factors that would improve
outcome and lead to a clinically useful classiﬁcation of “jux-
tarenal” and “type IV thoracoabdominal” aneurysms.
Statistical plan. Statistical analyses were performed us-
ing c2 or the Fisher exact test for categoric variables. Time-
to-event analyses of the long-term outcomes for survival,
freedom from reintervention, and freedom from the com-
posite end point (need for secondary intervention, branch
occlusion, stent migration, endoleak, aneurysm growth, or
spinal cord injury) are depicted graphically using Kaplan-
Meier curves. The recurrence of multiple branch-related
secondary interventions was also examined using a pro-
portional means model with sandwich variance estimators
to account for the within-patient correlation. Hazard ratios
(HRs) and 95% conﬁdence intervals (CIs) for recurrent
secondary interventions are provided for each graph clas-
siﬁcation (using the renals-only group as the reference).
Univariable and multivariable analysis for each
outcome was also performed to determine factors indepen-
dently associated with mortality, reintervention, and the
composite end point. Bootstrap sampling methods were
used to determine candidate variables for the multivariable
model. Variables included in the ﬁnal multivariable models
were retained at the a ¼ .20 level and met criteria from
bootstrapping sampling or were thought to be clinically
relevant (eg, age). All analyses were performed using SAS
9.2 software (SAS Institute Inc, Cary, NC).
RESULTS
All patients treated with juxtarenal and type IV repairs
between 2001 and December 2013 were reviewed, and
610 patients met the criteria to be included in this analysis,
with a mean of 8 years of follow-up. The demographics and
baseline characteristics are available in the Supplementary
Table. This includes 349 patients with type IV repair, 258
patients with juxtarenal repairs, and three patients who
remained unclassiﬁed due to missing documentation. For
the alternate classiﬁcation according to the original graft
design, the number of patients in each group and their base-
line demographics are also in the Supplementary Table.
Baseline demographics appeared to be balanced through
the four groups, with the exception of chronic obstructive
pulmonary disease, where people with renal fenestrations
were more likely to have this as a preoperative diagnosis
(P¼ .007). Technical success for these procedures was 97%.
Long-term outcomes. The survival curve for patients
undergoing juxtarenal or type IV TAAA repair in a
physician-sponsored investigational device exemption is
depicted in Fig 1, and outcomes are described in Table I.
Survival at 8 years was 20%, and aneurysm-related mor-
tality was 2%. Spinal cord injury occurred in seven patients
(1.16%). Spinal cord events did appear to be associated
with length of graft coverage: in the four patients with
spinal cord ischemia (SCI), the average length of coverage
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above the celiac fenestration was 52 6 21 mm, and the
average length for those not experiencing SCI was 33.4 6
21.4 mm, which was not statistically signiﬁcant (P ¼
.099). There was a trend to decreased survival for patients
with celiac fenestrations compared with all other graft
designs. The freedom from a composite outcome event,
including secondary intervention, branch occlusion, stent
migration, endoleak, aneurysm growth, or spinal cord
injury, is shown in Fig 2. Again, there was a trend toward
increased composite end point events in patients with
celiac fenestrations compared with lower stent designs.
Learning curve. The types of device used to treat jux-
tarenal and type IV TAAA over time are depicted in Figs 3
and 4. As experience evolved, the number of branches
included in repairs for type IV and juxtarenal aneurysm
types increased, despite similar anatomy.
Interventions performed over the lifetime of the devices
and long-term device-related complications are described in
Table II, subdivided by graft design. There was a higher inci-
dence of type I endoleak in the patients with only renal fen-
estrations, which may reﬂect the earlier inclusion of those
patients in the trial, and hence, earlier experience with the
Table I. Outcome through the entire follow-up period according to device design
Variables
Supraceliac
(n ¼ 58), No. (%)
Celiac scallop
(n ¼ 190), No. (%)
SMA or lower
(n ¼ 282), No. (%)
Renal or lower
(n ¼ 77), No. (%) P value
Classiﬁcation
Group IV 57 (98.3) 187 (98.4) 96 (34.0) 9 (11.7) <.001
Juxtarenal 1 (1.7) 3 (1.6) 186 (66.0) 68 (88.3)
Additional procedures 16 (27.6) 47 (24.7) 74 (26.2) 21 (27.3) .96
Additional procedures
None 42 (72.4) 143 (75.3) 208 (73.8) 56 (72.7)
1 14 (24.1) 34 (17.9) 53 (18.8) 16 (20.8)
2 0 (0.0) 10 (5.3) 18 (6.4) 2 (2.6)
$3 2 (3.4) 3 (1.6) 3 (1.1) 3 (3.9)
Patients with endoleak
Type I 2 (3.4) 2 (1.1) 6 (2.1) 8 (10.4) .002
Type II 10 (20.0) 32 (18.5) 43 (16.4) 12 (16.0) .88
Type III 5 (10.0) 9 (5.2) 7 (2.7) 7 (9.3) .03
Type IV 0 (0.0) 0 (0.0) 2 (0.8) 1 (1.3) .44
Unknown type 3 (6.0) 0 (0.0) 4 (1.5) 2 (2.7) .02
Occlusion during follow-up 12 (23.5) 14 (8.0) 21 (7.9) 4 (5.3) .002
Left renal 0 (0.0) 5 (2.9) 10 (3.9) 1 (1.4) .56
Right renal 0 (0.0) 2 (1.2) 8 (3.0) 3 (4.2) .29
SMA 0 (0.0) 3 (1.7) 3 (1.1) 0 (0.0) .85
Celiac 2 (3.4) 3 (1.6) 0 (0) 0 (0) .02
Stent fracture 0 (0.0) 3 (1.6) 8 (3.0) 3 (4.1) .44
Component separation 1 (1.9) 1 (0.5) 2 (0.8) 3 (4.2) .08
Aneurysm growth 3 (5.2) 4 (2.1) 13 (4.6) 2 (2.6) .42
Stent migration 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.3) .22
Rupture 3 (5.2) 2 (1.1) 8 (2.8) 1 (1.3) .22
SMA, Superior mesenteric artery.
Fig 1. Survival for patients with juxtarenal and group IV aneurysms treated with (A) fenestrated (Fen) endograft and
(B) by device morphology. SMA, Superior mesenteric artery.
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device or the longer follow-up. Details of the patients with
type I endoleak were reported in detail in a previous
publication.5
Branch complications. A total of 1463 branches un-
derwent repair (17 celiac, 312 SMA, 570 left renal,
and 564 right renal). HRs for risk of branch complications
as analyzed by individual branch risk are reported in
Table III. Devices with landing zones above the celiac ar-
tery requiring fenestrations for all visceral vessels appeared
to have poorer branch outcomes, even when controlling
for the number of branches within the device. The risk of
celiac occlusion over time was higher in patients with a
supraceliac landing zone compared with those with celiac
scallops or lower (3.5% vs 0.5%; P ¼ .019).
Fig 3. Three-dimensional reconstructions of devices. Fenestrated devices are shown with (A) renal fenestrations, (B) a
single-wide scallop for the superior mesenteric artery (SMA), and with (C) a double-wide scallop for the celiac artery.
D, Fenestrated device is shown landing in the supraceliac aorta.
Fig 2. Composite end point in (A) all patients and (B) by device design. Fen, Fenestrated.
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The use of stents for single-wide scallops was assessed.
In the 213 patients with a scallop to the SMA, 26 were
stented and 187 were unstented, in both cases due to the
surgeon’s preference at the time of the operation.
There was no statistically signiﬁcant difference in
1-year mortality (P ¼ .352), SMA occlusion (P ¼ 1),
component separation (P ¼ 1), or aneurysm growth
or rupture (P ¼ 1) between the patients with stented vs
Fig 4. Type of device used to treat (A) group IV thoracoabdominal aortic aneurysm (TAAA) and (B) juxtarenal (JR)
aneurysm over time. Fen, Fenestrated; SMA, superior mesenteric artery.











Celiac 1 0 N/A N/A
SMA 2 9 14 N/A
Renal 9 25 29 9
Device body 4 3 9 8
Device limbs 3 6 13 5
Embolization 4 8 18 7
Remote aneurysm 1 1 1 1
Other extremity 4 12 24 3
Other 0 3 4 3
Total 28 67 112 36
N/A, Not applicable; SMA, superior mesenteric artery.







No. HR (95% CI)
P
value
Supraceliac 12 8 58 2.20 (0.74-6.61) .16
Celiac
scallop
34 27 190 1.75 (0.82-3.72) .15
SMA 43 36 282 1.24 (0.62-2.49) .55
Renal 11 9 77 Reference
CI, Conﬁdence interval; SMA, superior mesenteric artery.
aPatients may have multiple complications.
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nonstented SMA single-wide scallops. However, Fig 5
demonstrates the long-term need for reinterventions
and the freedom from the composite end point between
these two groups, for which there was no statistically
signiﬁcant difference. It is informative that the reinter-
vention curves diverge after 15 months, suggesting
the stented scallops need more intervention in the
long-term.
To increase sample size, we also analyzed the entire
population of people with single-wide scallops, and the
need for reintervention and freedom from composite
endpoint curves are in Fig 6, which also showed no
statistically signiﬁcant difference. When single-wide scal-
lops for SMA or renal arteries were used, there was no
different in mortality at 1 year (7 of 61 [11.5%] stented
vs 23 of 200 [11.5%] unstented, P ¼ .996), reinterven-
tion (6 of 61 stented vs seven of 200 unstented; P ¼
.084), or occlusion (4 of 61 stented vs 12 of 200
unstented; P ¼ 1) for patients with initially stented scal-
lops vs unstented.
Univariate and multivariate analysis. Univariate and
multivariate analyses for the end point of mortality and
the composite end points of need for secondary inter-
vention, branch occlusion, stent migration, endoleak,
Fig 5. Time-to-event analysis for single-wide scallops for the superior mesenteric artery (SMA) and reintervention over
time. A,Depicts single-wide scallops only in the SMA and need for reintervention. B, Represents single-wide scallops in
SMA and freedom from composite end point.
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aneurysm growth or spinal cord injury are reported in
Tables IV and V.
DISCUSSION
We report the use of fenestrated devices in patients
classiﬁed by the treating surgeon as having a type IV
TAAA or juxtarenal repair over a 12-year experience.
Long-term survival in this population was 20% after a
mean of 8 years of follow-up, and long-term aortic-
related mortality was 2% in the same follow-up period.
There was a trend toward poorer survival in patients
with a supraceliac landing zone compared with other
conﬁgurations. The long-term risk of SCI was 1.16%.
There was a greater risk of SCI with increasing graft
coverage above the celiac artery (52 mm compared
with 33 mm; P ¼ .099). Over the course of the
follow-up, the rate of type I endoleak was greater in pa-
tients with renal fenestrations (8 of 77 [10.4%]; P #
.01), and the rate of celiac occlusion was greater in pa-
tients with supraceliac landing zones (3.5% vs 0.5%,
P ¼ .019). There was a trend toward a greater rate of
overall branch reintervention in patients with supraceliac
landing zones compared with other conﬁgurations (HR,
2.20; 95% CI, 0.74-6.61; P ¼ .16). The type of device
used to treat similar anatomy over time has evolved
and has become more complex.
Fig 6. Time-to-event analysis for all single-wide scallops. A, Depicts need for reintervention in single-wide scallops. B,
Represents freedom from composite end point for single-wide scallops.
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There have been numerous reports of perioperative
outcomes for fenestrated devices in the literature, but
very few report long-term results (Table VI).4,12-23 The
combined weighted estimated perioperative mortality for
patients undergoing fenestrated repair is 2.3% (95% CI,
1.4-3.2; standard error, 0.005) if data from 13 series are
included. SCI is rarely reported in patients with juxtarenal
or type IV TAAA, but in the few publications in which an
event occurred, the incidence was low.
Long-term follow-up in patients undergoing fen-
estrated stent grafting is less commonly reported.
Kristmundsson et al23 reported their experience after
67 months of follow-up. Aneurysm diameter decreased
>5 mm in 71% 6 8% and target vessel patency was
90% 6 3% at 60 months. The need for at least one reinter-
vention occurred in 37% of patients, and the reason for
intervention was related to endoleak in 29%, the target
vessel in 26%, the graft limb in 13%, and was due to a va-
riety of other causes in 32%. Overall survival was 60% 6
7% at 60 months, with only 9% of deaths accounted for
by aneurysm-related causes.
The trend of poorer long-term outcomes for patients
treated with a device that requires coverage above the ce-
liac artery may provide some insight into future reporting
standards. It has long been our contention that the Craw-
ford classiﬁcation may be outdated and thus not appro-
priate for prognostication in endovascular repair of
TAAA. In fact, despite classiﬁcation as “type IV TAAA”
by one of three experienced surgeons, patients in our study
with devices that included scallops to the celiac or lower
designs seemed to have similar outcomes, suggesting a clas-
siﬁcation system that dichotomizes anatomy to repairs
above or below the celiac axis may be sufﬁcient to provide
prognostic information.
Although extracting a deﬁnitive conclusion about the
risk of increasing the coverage of the visceral aorta to improve
the durability of repair from these data is difﬁcult because of
the unknown effect that experience and learning had on the
Table V. Univariable and multivariable analysis of patient characteristics associated with the composite end pointa
Variable
Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Age per 5-year increase 0.95 (0.86-1.04) .26 0.96 (0.87-1.05) .34b
Male 0.92 (0.64-1.34) .68 c
Smoker 1.12 (0.74-1.69) .60 c
Diabetes 0.97 (0.67-1.39) .85 c
Hypertension 1.46 (0.97-2.21) .07 1.46 (0.96-2.20) .08
Cardiovascular disease 0.96 (0.72-1.27) .77 c
Congestive heart failure 0.86 (0.57-1.28) .45 c
Previous CVA/TIA 1.01 (0.70-1.46) .96 c
Arrhythmia/pacemaker 0.79 (0.57-1.11) .17 c
Chronic obstructive pulmonary disease 0.84 (0.62-1.15) .28 c
Lung cancer 2.43 (1.24-4.76) .01 2.41 (1.23-4.74) .01
Previous aneurysm repair 1.34 (0.84-2.16) .22 c
CI, Conﬁdence interval; CVA, cerebrovascular accident; HR, hazard ratio; TIA, transient ischemic attack.
aThe composite end point is deﬁned as need for secondary intervention, branch occlusion, stent migration, endoleak, aneurysm growth, or spinal cord injury.
bAlthough this did not meet the criteria for inclusion, it was retained for clinical importance.
cClinical factors that did not meet the a ¼ .2 level for inclusion during bootstrap modeling.
Table IV. Univariable and multivariable analysis of patient characteristics associated with mortality
Variable
Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Age, per 5-year increase 1.23 (1.14-1.34) <.0001 1.29 (1.19-1.40) <.0001
Male 0.84 (0.62-1.13) .25 0.75 (0.55-1.02) .06
Smoker 0.97 (0.70-1.34) .84 a
Diabetes 1.17 (0.88-1.55) .28 a
Hypertension 0.98 (0.74-1.31) .92 a
Cardiovascular disease 0.91 (0.72-1.14) .40 a
Congestive heart failure 1.79 (1.37-2.33) <.0001 2.20 (1.66-2.90) <.0001
Previous CVA/TIA 1.00 (0.75-1.34) .98 a
Arrhythmia/pacemaker 1.20 (0.94-1.53) .15 a
Chronic obstructive pulmonary disease 1.10 (0.87-1.40) .43 1.19 (0.93-1.51) .17
Any cancer 1.50 (0.82-2.75) .19 1.52 (1.16-2.00) .002
Previous aneurysm repair 1.62 (1.08-2.43) .02 1.82 (1.21-2.75) .004
CI, Conﬁdence interval; CVA, cerebrovascular accident; HR, hazard ratio; TIA, transient ischemic attack.
aClinical factors that did not meet the a ¼ .2 level for inclusion during bootstrap modeling.
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device design over time, there appears to be no increased risk
to including a celiac scallop compared with simple renal or
SMA fenestrated devices. The increased rate of endoleak
with lower designs provides further evidence that sealing in
the midvisceral aorta (ie, between the renal arteries and
SMAs) may not be as desirable as a design that includes a
scallop to the celiac artery. This may suggest that a more
standardized conﬁguration for juxtarenal aneurysms, with
three fenestrations and a wide scallop, may be appropriate
and provide a more durable long-term result even though
the length of sealing is longer than currently required.
In performing this analysis, we had also hoped to inform
the decision to stent or not stent a single-wide scallop. The
bias of our group has evolved to treat a single-wide scallop,
much like a small fenestration, with a stent. This grew
from the experience of one patient whose unstented SMA
occluded, causing death in the perioperative period.3 In
reviewing our outcomes, it became apparent that our prac-
tice has evolved away from the use of single-wide scallops
in any anatomy after this event. We have shown a nonstatisti-
cally signiﬁcant trend for increased reintervention for stented
single-wide scallops in the long-term, but this is difﬁcult to
interpret because of the predominant use of uncovered stents
in early experience, which may bias the need for reinterven-
tion. Although our intention was that this analysis would put
an end to the debate about the importance of stenting single-
wide scallops, the small numbers and the effect of learning
curve suggest that no deﬁnitive conclusions can be made.
We report an increased risk of need for reintervention in
patients with more complex grafts and a higher rate of celiac
occlusions in patients with landing zones above the celiac ar-
tery. This combination of ﬁndings could be attributed to the
increased complexity of these repairs, leaving more compo-
nents available for materiel fatigue or malfunction. However,
it is also compelling to consider that this may suggest that
the conﬁguration of the celiac artery, which is frequently
quite downward going and may include an element of
external compression from the median arcuate ligament,
may not be ideally suited for treatment with a fenestration,
and this has biased the overall branch durability. Experienced
users have observed the challenge of routine placement of a
mating stent into the celiac artery when coupled with a
fenestration compared with the ease of stenting from a
branch. It may be that an ideal design for anatomy requiring
coverage above the celiac artery incorporates a downward
going branch and a delivery system that facilitates placement
of a mating stent from an antegrade aortic direction. In the
small group of patients with landing zones above the celiac
artery, technical success was low: 173 of 185 (93.5%).
CONCLUSIONS
Overall, the use of fenestrated devices in type IV and jux-
tarenal aneurysms is safe over the long-term, with a 2% aortic-
related mortality over an 8-year mean follow-up and 12 years
of experience. The need for reinterventions is increased with
complexity of design, but the incidence of type I endoleak ap-
pears to occur more frequently if shorter sealing zones are
chosen, although this may be biased by the learning curve.
Further research is needed to ﬁnd a method of incorporation
of the celiac artery to decrease the risk of spinal ischemia and
celiac occlusion while also allowing for maximal coverage and
landing in healthy aortic tissue. Future reporting standards for
complex endovascular repair should consider a dichotomous
classiﬁcation system of supraceliac or infraceliac landing zones
to predict spinal cord events and mortality.
This report would not be possible without the lifetime
contributions of Dr Roy K. Greenberg, whose vision in
starting a prospective trial evaluating the use of complex
endovascular treatments for aneurysm disease is paying div-
idends to the ﬁeld now and will for many years to come.
For this, we are eternally grateful.
AUTHOR CONTRIBUTIONS
Conception and design: TM, ME
Analysis and interpretation: TM, ME, KW
Data collection: TM, YK, SB, KW
Writing the article: TM, KW
Critical revision of the article: TM, KW, ME
Final approval of the article: TM
Statistical analysis: KW
Obtained funding: Not applicable
Overall responsibility: TM
REFERENCES
1. Browne TF, Hartley D, Purchas S, Rosenberg M, Van SG, Lawrence-
Brown M. A fenestrated covered suprarenal aortic stent. Eur J Vasc
Endovasc Surg 1999;18:445-9.
2. Kristmundsson T, Sobocinski J, Sonesson B, Dias N, Haulon S,
Resch T. Early versus late experience in fenestrated endovascular repair
for abdominal aortic aneurysm. J Vasc Surg 2013;57:17s.
3. Mastracci TM, Greenberg RK, Eagleton MJ, Hernandez AV. Dura-
bility of branches in branched and fenestrated endografts. J Vasc Surg
2013;57:926-33; discussion: 933.
Table VI. Published literature on perioperative
outcomes for fenestrated endografts








Grimme22 2014 138 2 13
Amiot121 2009 134 1 3 15
BSET16 2012 318 5 13
Greenberg CCF JR 2010 227 4
Greenberg
(U.S. Trial)18
2009 30 0 0 2
Donas17 2012 29 0
Kristmundsson20 2009 54 0 2 12
Manning15 2011 20 2
Mertens14 2012 2 0
Scurr13 2007 45 0 2 5
Semmens12 2006 58 1 2 8
Tambyraja19 2011 29 4 0 4
Verhoeven4 2010 100 23 1
BSET, British Society for Endovascular Therapy; SCI, spinal chord ischemia.
JOURNAL OF VASCULAR SURGERY
Volume 61, Number 2 Mastracci et al 363
4. Verhoeven EL, Vourliotakis G, Bos WT, Tielliu IF, Zeebregts CJ,
Prins TR, et al. Fenestrated stent grafting for short-necked and jux-
tarenal abdominal aortic aneurysm: an 8-year single-centre experience.
Eur J Vasc Endovasc Surg 2010;39:529-36.
5. O’Callaghan A, Greenberg RK, Eagleton M, Bena J, Mastracci TM.
Type Ia endoleaks following fenestrated and branched endografts may
lead to component instability and increased aortic mortality. J Vasc
Surg 2014;59:1479-87.
6. Katsargyris A, Oikonomou K, Klonaris C, Topel I, Verhoeven EL.
Comparison of outcomes with open, fenestrated, and chimney graft
repair of juxtarenal aneurysms: are we ready for a paradigm shift?
J Endovasc Ther 2013;20:159-69.
7. Greenberg RK, Lu Q, Roselli EE, Svensson LG, Moon MC,
Hernandez AV, et al. Contemporary analysis of descending thoracic
and thoracoabdominal aneurysm repair: a comparison of endovascular
and open techniques. Circulation 2008;118:808-17.
8. O’Neill S, Greenberg RK, Haddad F, Resch T, Sereika J, Katz E.
A prospective analysis of fenestrated endovascular grafting:
intermediate-term outcomes. Eur J Vasc Endovasc Surg 2006;32:
115-23.
9. Mohabbat W, Greenberg RK, Mastracci TM, Cury M, Morales JP,
Hernandez AV. Revised duplex criteria and outcomes for renal stents
and stent grafts following endovascular repair of juxtarenal and thor-
acoabdominal aneurysms. J Vasc Surg 2009;49:827-37.
10. Dowdall JF, Greenberg RK, West K, Moon M, Lu Q, Francis C, et al.
Separation of components in fenestrated and branched endovascular
graftingdbranch protection or a potentially new mode of failure? Eur J
Vasc Endovasc Surg 2008;36:2-9.
11. Fillinger MF, Greenberg RK, McKinsey JF, Chaikof EL. Reporting
standards for thoracic endovascular aortic repair (TEVAR). J Vasc Surg
2010;52:1022-33. 1033.e15.
12. Semmens JB, Lawrence-Brown MM, Hartley DE, Allen YB, Green R,
Nadkarni S. Outcomes of fenestrated endografts in the treatment of
abdominal aortic aneurysm in Western Australia (1997-2004).
J Endovasc Ther 2006;13:320-9.
13. Scurr JR, Brennan JA, Gilling-Smith GL, Harris PL, Vallabhaneni SR,
McWilliams RG. Fenestrated endovascular repair for juxtarenal aortic
aneurysm. Br J Surg 2008;95:326-32.
14. Mertens R, Bergoeing M, Marine L, Valdes F, Kramer A, Vergara J.
Ventana fenestrated stent-graft system for endovascular repair of jux-
tarenal aortic aneurysms. J Endovasc Ther 2012;19:173-8.
15. Manning BJ, Agu O, Richards T, Ivancev K, Harris PL. Early outcome
following endovascular repair of pararenal aortic aneurysms: triple-
versus double- or single-fenestrated stent-grafts. J Endovasc Ther
2011;18:98-105.
16. British Society for Endovascular Therapy and the Global Collaborators
on Advanced Stent-Graft Techniques for Aneurysm Repair (GLOB-
ALSTAR) Registry. Early results of fenestrated endovascular repair of
juxtarenal aortic aneurysms in the United Kingdom. Circulation
2012;125:2707-15.
17. Donas KP, Eisenack M, Panuccio G, Austermann M, Osada N,
Torsello G. The role of open and endovascular treatment with fenes-
trated and chimney endografts for patients with juxtarenal aortic an-
eurysms. J Vasc Surg 2012;56:285-90.
18. Greenberg RK, Sternbergh WC 3rd, Makaroun M, Ohki T, Chuter T,
Bharadwaj P, et al. Intermediate results of a United States multicenter
trial of fenestrated endograft repair for juxtarenal abdominal aortic
aneurysms. J Vasc Surg 2009;50:730-7.
19. Tambyraja AL, Fishwick NG, Bown MJ, Nasim A, McCarthy MJ,
Sayers RD. Fenestrated aortic endografts for juxtarenal aortic aneurysm:
medium term outcomes. Eur J Vasc Endovasc Surg 2011;42:54-8.
20. Kristmundsson T, Sonesson B, Malina M, Bjorses K, Dias N, Resch T.
Fenestrated endovascular repair for juxtarenal aortic pathology. J Vasc
Surg 2009;49:568-74.
21. Amiot S, Haulon S, Becquemin JP, Magnan PE, Lermusiaux P,
Gouefﬁc Y, et al. Fenestrated endovascular grafting: the French mul-
ticentre experience. Eur J Vasc Endovasc Surg 2010;39:537-44.
22. Grimme FA, Zeebregts CJ, Verhoeven EL, Bekkema F, Reijnen MM,
Tielliu IF. Visceral stent patency in fenestrated stent grafting for
abdominal aortic aneurysm repair. J Vasc Surg 2014;59:298-306.
23. Kristmundsson T, Sonesson B, Dias N, Tornqvist P, Malina M,
Resch T. Outcomes of fenestrated endovascular repair of juxtarenal
aortic aneurysm. J Vasc Surg 2014;59:115-20.
Submitted Jul 15, 2014; accepted Sep 29, 2014.











(n ¼ 77) P value
Male 501 (82.1) 50 (86.2) 158 (83.2) 227 (80.5) 65 (84.4) .67
Smoking status 563 50 176 261 74 .97
Never 43 (7.6) 2 (4.0) 14 (8.0) 22 (8.4) 5 (6.8)
Former 407 (72.3) 38 (76.0) 126 (71.6) 187 (71.6) 54 (73.0)
Current 113 (20.1) 10 (20.0) 36 (20.5) 52 (19.9) 15 (20.3)
Age, years 75.2 6 7.64 74.4 6 7.59 75.5 6 7.42 75.2 6 7.90 75.5 6 7.42 .79
History of
Cardiac disordersc 333 (54.6) 25 (43.1) 110 (57.9) 155 (55.0) 43 (55.8) .26
Diabetes (type 1 or 2) 119 (19.5) (10.3) 34 (17.9) 65 (23.0) 13 (16.9) .11
Aortic or mitral valve regurgitation 34 (5.6) 0 (0.0) 10 (5.3) 17 (6.0) 7 (9.1) .11
Arrhythmia or use of pacemaker 170 (27.9) 15 (25.9) 47 (24.7) 86 (30.5) 21 (27.3) .57
COPD 190 (31.1) 17 (29.3) 51 (26.8) 84 (29.8) 37 (48.1) .007
Lung cancer 18 (3.0) 2 (3.4) 5 (2.6) 7 (2.5) 4 (5.2) .57
Elephant trunk repair 0 0 0 0 0 e
Aneurysm repair 56 (9.2) 13 (22.4) 31 (16.3) 10 (3.5) 2 (2.6) <.001
COPD, Chronic obstructive pulmonary disease; Fen, fenestration; SMA, superior mesenteric artery.
aCategoric data are presented as number (%) and continuous data as mean 6 standard deviation.
bThree patients were unclassiﬁed due to missing documentation.
cIncludes stable/unstable angina, myocardial infarction, coronary artery bypass grafting, and percutaneous intervention.
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